GSK

#Investors: Join GSK’s CEO, Luke Miels, and other members of our leadership team for our Q3 2026 results webcast at 12:00 GMT, 08:00 EDT. $GSK

We’re announcing our Q3 2026 results tomorrow at 07:00 GMT, 03:00 EDT. $GSK

#News for #investors and #media: Today, our licensor Hansoh Pharma presented new Phase 3 data in osteosarcoma, building on ongoing research efforts for patients with difficult-to-treat solid tumours. #ESMO2026 Learn more: gsk.to/3TZ5Yq9

#News for #Investors and #Media: Today, we presented data from one of our immunotherapies used to treat people living with colorectal cancer. Read more: gsk.to/3VTGgUy #ESMO2026

#News for #Investors and #Media: Today, we presented longer-term late-breaking data, marking encouraging progress for people living with ovarian cancer. #ESMO2026 Learn more: gsk.to/3Uh1bAd

#News for #investors & #media: Today marks an important milestone in chronic hepatitis B (CHB), with the U.S. FDA approving a new therapy for people living with the disease. This approval reflects years of research and a continued commitment to advancing innovation in liver disease, where significant unmet need remains. Learn more: gsk.to/4Bisj2s

#News for #Investors and #Media: The US Food and Drug Administration (FDA) has approved a new indication for one of our immunotherapies. Read more: gsk.to/4iwAy2D

#News for #Investors and #Media: Today, we shared the first data for our investigational treatment for extensive-stage small-cell lung cancer in a global population. Learn more: gsk.to/4z38aw4 #ESMO2026

#News for #Investors and #Media: At ESMO 2026, we're showcasing over 20 abstracts from our oncology portfolio and pipeline, underscoring our expansion into solid tumours like lung, gynaecological, gastrointestinal, and GIST. Read more:gsk.to/4dCmnr6 #ESMO2026

Dementia is one of the greatest health challenges facing society today. We're proud to support The BARBARA Alliance in a major new partnership, announced today by UK Government, bringing together academia, charities and industry to help accelerate research. Read more here: gsk.to/4doDhJG

#News for #Investors and #Media: Today our specialist HIV company, @ViiVHC, announced phase III study results in #HIV evaluating a long-acting option versus daily oral therapy. Our mission: to leave no person living with HIV behind. 👉 Find out more: gsk.to/3VpWIM1

#News for #investors and #media: We have entered a licence agreement with Chimagen Biosciences for an investigational T-cell engager for multiple myeloma, advancing our leadership ambitions in blood cancer. Find out more: gsk.com/en-gb/media/press-re…

#News for #investors and #media: Today, we announced new positive data at #WCLC26 representing encouraging news for people living with ROS1-positive non-small cell lung cancer. Learn more: gsk.to/4xolucI

#News for #investors and #media: Today, our licensor Hansoh Pharma presented positive data at #WCLC26 from a pivotal trial of an investigational antibody-drug conjugate in our pipeline. Learn more: gsk.to/4xRUa7t

#News for #Investors and #Media: Japan’s Ministry of Health, Labour and Welfare (MHLW) has approved a new prefilled syringe presentation of one of our vaccines. Learn more: gsk.to/4xSAW1Q

The data we’ve shared at #ERSCongress underscores how much more we can achieve for respiratory patients when science and partnership come together. Building on our proven track record of innovation, we’re accelerating our R&D programmes in COPD to target multiple inflammatory pathways, aiming for ambitious trial outcomes that look beyond the disease impact on the lungs so that we can transform outcomes for a broad range of patients, with varying severities of disease. #ERSCongress

#Media #Investors Climate change is one of the greatest threats to human health, and its impact on patients with respiratory health conditions should not be underestimated. Through advances in sustainable respiratory care, we’re making progress towards our environmental goals. Read the media statement gsk.to/4iFXSfO

#News for #Investors and #Media: Today we announced Phase II data for a seasonal flu vaccine candidate at #OPTIONSXIII. Learn more: gsk.to/3Sqbt0e